Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.

Inclusion Criteria:

• Men or women must be at least 18 years of age at the time of screening

• Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization Patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by:

• PASI score of >10

• Affected body surface area (BSA) > 10%

• DLQI >10

• Inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening.

Exclusion Criteria (abbreviated):

• Previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at baseline

• Ongoing use of other prohibited psoriasis and non-psoriasis treatment.

• Clinically important active infections or infestations, chronic, recurrent or latent infections or infestations

• Patients with severe liver diseases

• Patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers

• Patients with severe kidney diseases or serum creatinine above 1 x ULN

• Patients with known hematological disease or lab abnormalities

• Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if necessary)